Navigation Links
Breakthrough in Migraine Treatment
Date:11/8/2011

LIEGE, Belgium, November 8, 2011 /PRNewswire/ --

PREMICE clinical trial proves Cefaly® medical device efficacy in migraine prevention and points out that Cefaly® has the best safety-efficacy ratio compared to other treatments.

On Monday 7th of November a press conference took place in Liege Science Park. Professor Jean Schoenen, principal investigator, neurologist and professor at Liege University (Belgium) presented the results of PREMICE (Prevention Migraine Cefaly) a multicenter randomized double-blind placebo controlled clinical trial for migraine prevention with the Cefaly® neurostimulator.

The clinical trial was conducted in 5 Belgian university hospitals on 67 patients. The results prove the efficacy of the Cefaly® compared to placebo for migraine prevention. At 3 months of treatment the 50% responder rate was significantly greater in the Cefaly® group (38,1%) than in the placebo group (12,1%). Seventy percents of patients declared they were satisfied or very satisfied with the Cefaly® treatment. The drug consumption reduction is very impressive in the Cefaly® group (-37%) compared to the placebo group (+0.5%). Cefaly® responder group drug consumption reduction was -75%!

Without noticeable side effects or contraindications, Cefaly® is very safe. Cefaly® has a similar efficacy than preventative drugs, but without side effects. Consequently, Cefaly® has the best safety-efficacy ratio of all migraine treatments.

Prof. Schoenen: "This clinical trial has been implemented according to the highest quality standard and it proves that Cefaly® is efficient for migraine prophylaxis. Efficacy is similar with the most efficient preventative drugs but with the great advantage of having no side effects."

Cefaly® is an innovative medical device protected by a series of patents. This is the first cranial external neurostimulation device on the market. Cefaly® neurostimulation is applied to the upper branch of the trigeminal nerve. A self-adhesive electrode is applied on the forehead and the device is placed on this electrode in the position of a pair of glasses. Very accurate pulses are transmitted through the electrode to the nerve endings of the trigeminal nerve.

STX-Med Company is a startup based in Liege (Belgium), which launched the Cefaly® technology project in 2005. The company STX-Med is ISO Medical. Cefaly® device has the medical CE-marked. It is available on the European market for 295 € and in Canada as well.

http://www.cefaly.com/


'/>"/>
SOURCE STX-Med
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genetic Profile Identified for Alzheimers Patients Showing Heightened Response to Acceras Breakthrough Product Axona®
2. Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S.
3. SensoScientific Awarded Contract by Premier Health Care Alliance for its Breakthrough WI-FI Temperature Monitoring System
4. Major Diagnostic Breakthrough in Multiple Sclerosis Achieved with Advanced FONAR UPRIGHT® MRI
5. Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis
6. Aging-in-Place Research Breakthroughs To Be Presented At Wireless Health 2011 Conference
7. Molecular Devices Releases Breakthrough TUNE Technology, Now Part of the SpectraMax® Paradigm® Multi-Mode Microplate Detection Platform
8. aTyr Pharma Expands Leadership Team to Advance New Breakthrough Medicines Based on Physiocrine Biology
9. Report on HIV Prevention Research Funding Says New Investment Critical to Capitalize on HIV Prevention Research Breakthroughs
10. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
11. CT Scans Unleash a Breakthrough in Catching Early Stage Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Yissum Research Development Company ... that it had signed an exclusive world-wide licensing and ... novel protein degradation and immunomodulatory drugs for cancer and ... candidates representing first-in-class therapy for hematologic and solid malignancies. ... The novel technology was developed by Yinon ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Ischemic Stroke Market ... to their offering.       (Logo: ... Global Acute Ischemic Stroke Market and Competitive ... Acute Ischemic Stroke pipeline products, Acute Ischemic ...
(Date:5/3/2016)... Global Insulin Needles Industry ... key companies and supported with 272 tables and ... on the current state of the Insulin Needles ... including definitions, classifications, applications and industry chain structure. ... the international market including development history, competitive landscape ...
Breaking Medicine Technology:
(Date:5/5/2016)... , ... May 05, 2016 , ... ... Drago presented a talk highlighting the organization’s successful Care Transitions program ... , The talk was titled “Minimizing Costs in the Post-Acute Environment Through Effective ...
(Date:5/5/2016)... CA (PRWEB) , ... May 05, 2016 , ... The ... the Year, Derek Pittman, along with his university coaching staff. Together they bring their ... with separate sessions run for youth players ages 5-13, and high school players. Session ...
(Date:5/5/2016)... (NEW YORK, New York) , ... (PRWEB) May 05, 2016 , ... ... partnership with healthcare talent acquisition startup, HireNurses, on the eve of National Nurses ... for job seeking nurses and healthcare employers. With their enrollment into the Talent Tech ...
(Date:5/5/2016)... ... 05, 2016 , ... United Collection Bureau, Inc. (UCB) announces Sarah Clark as ... years of experience within the healthcare revenue cycle industry. With a primary focus of ... Patient Financial Services at Spectrum Health. While at Spectrum Health, Clark helped Spectrum achieve ...
(Date:5/5/2016)... ... ... Institute will celebrate its three-year anniversary on May 14 by giving away a free ... May. To date, the Lung Institute has treated over 2,000 people at their five clinics ... the success of this treatment and to the patients who refuse to give up,” says ...
Breaking Medicine News(10 mins):